Clear, evidence-based explanations of cutting-edge cancer treatment strategies — so you can have more informed conversations with your care team.
Why treating cancer cells alone is no longer enough — and what a more complete picture of the disease means for how we treat it.
For decades, cancer treatment has followed a relatively straightforward logic: find the mutation, target the tumour cell, eliminate the disease. This approach has delivered real progress — but it does not fully explain why so many patients fail therapy, develop resistance, or relapse despite receiving what appeared to be the right treatment. A major synthesis published in Cell offers a more complete framework: cancer behaves as a dynamic ecosystem, not an isolated mass of malignant cells.
Within any tumour, there is no uniform biology. Tumours are organised into spatially distinct zones — each with its own immune landscape, metabolic behaviour, and resistance potential. Understanding these zones is as important as understanding the tumour's genetics.
Standard biomarkers like PD-L1 expression and immune cell counts measure how many immune cells are present. But this framework reveals a critical limitation: what matters equally is where those cells are and whether they can function.
Tumours labelled as "immune cold" may actually contain immune cells that are trapped at the periphery, blocked by stromal barriers, or metabolically suppressed within hypoxic zones. The immune system is present — it just cannot act. This directly explains why immunotherapy fails in patients who appear to be good candidates on paper.
The tumour ecosystem is not static. It continuously adapts under immune pressure, therapeutic intervention, and metabolic stress. Critically, immune escape can begin before a tumour is even detectable, and dormant cancer cells can persist for years before reactivating.
This reframes disease progression: it is not only genetic evolution — it is ecological adaptation. A tumour that responds initially and then relapses has not simply mutated. It has reorganised its environment to survive.
Perhaps the most underappreciated insight is that tumour behaviour is profoundly shaped by the patient's broader physiology — what the paper calls the systemic macroenvironment. Factors including age, sex, obesity, diet, chronic inflammation, and even environmental exposures all influence immune tone and treatment responsiveness.
If cancer is an ecosystem, therapy must do more than kill tumour cells. The emerging approach is ecosystem reprogramming — dismantling the networks that sustain the tumour rather than targeting individual cells in isolation. This includes modulating stromal barriers, normalising tumour vasculature, restoring immune spatial access, and factoring in the patient's systemic biology.
We are still using tumour-infiltrating lymphocyte therapy too late — and the data makes a compelling case for changing that.
For years, TIL therapy in advanced melanoma has been treated as a last resort — something to consider only after everything else has failed. But the data tells a very different story, and the oncology community needs to reckon with what that means for how and when we offer this treatment to patients.
Response rates in the range of 30–50% are being observed in heavily pretreated patients — including those who have already progressed on anti–PD-1 and targeted therapies. For a population with such limited remaining options, that level of activity is not just encouraging. It is remarkable.
TIL therapy is inherently complex. It requires tumour resection, ex vivo expansion of lymphocytes, lymphodepleting chemotherapy, infusion, and IL-2 support. Each of these steps demands that a patient be in a condition where they can tolerate the process.
That means adequate performance status, preserved organ function, and a resectable lesion. That window of eligibility is not indefinite. If we wait too long, we risk losing the opportunity to use TIL therapy entirely — not because the treatment failed, but because the patient was no longer fit enough to receive it.
From a precision oncology perspective, one of the most impactful shifts we can make right now is not simply developing the next generation of TIL products. It is changing how and when we think about using them.
TIL therapy should not be an afterthought reserved for late-line settings. It should be part of the treatment conversation earlier — when patients are still fit enough to benefit from it. The field is beginning to move in this direction, but not nearly fast enough.
Until referral patterns change, the clinical potential of TIL therapy will continue to be underutilised — not because it doesn't work, but because we are reaching for it too late. The question is no longer whether TIL therapy is effective. The question is whether we are giving patients the chance to receive it while they still can.
Exploiting Replication Stress in CCNE1-Amplified Tumours · Au-Yeung G et al., Journal of Clinical Oncology (2023)
Inside every cell, there is a tightly controlled process called the cell cycle — the system that decides when a cell should divide and make a copy of itself. In healthy cells, this process has multiple checkpoints, like traffic lights, that ensure everything is correct before division proceeds. In certain cancers, these safeguards break down in a very specific and exploitable way.
In some cancers, a gene called CCNE1 is amplified — meaning the body produces far too many copies of it. This floods the cell with a protein called Cyclin E1, which teams up with another protein called CDK2 and essentially puts the accelerator down on cell division. To make things worse, many of these same tumours also carry a TP53 mutation — meaning the cell's most important "stop" signal is broken. Think of it as a car with a stuck accelerator and no brakes.
When the primary braking system (TP53) is broken, cancer cells become entirely dependent on their remaining checkpoints to survive. These are controlled by proteins called WEE1, PKMYT1, and ATR — which become the cancer cell's last safety net.
This dependency is actually an opportunity. By using drugs that block these proteins — or by directly targeting the CDK2 complex — scientists can knock out those last remaining checkpoints, causing the cancer cells to self-destruct while largely sparing healthy cells.
CCNE1 amplification is particularly common in:
These are often cancers that have stopped responding to standard platinum-based chemotherapy, making new targeted strategies urgently needed.
Important context: Several WEE1 and CDK2 inhibitors are currently in active clinical trials. This is an area of rapid development — if your cancer carries CCNE1 amplification, discussing clinical trial eligibility with your oncology team is worthwhile.
Schmitt, Gätje, Tran et al. — Molecular Cancer (2026)
Pancreatic ductal adenocarcinoma (PDAC) has two main molecular subtypes — classical and basal — which have different metabolic profiles and have historically been thought to require different treatments. This study used spatial RNA sequencing across 14 patient tumours to challenge that assumption.
Both classical and basal tumours contain "metabolically hot" niches — aggressive zones where glycolysis and fat production are simultaneously elevated. These appear in both subtypes, making them a potential shared therapeutic target.
The study traced a classical-to-basal progression within individual tumours — showing how pancreatic cancers become more aggressive over time at a molecular level.
Inhibiting PFKFB3, a key driver of glycolysis, shifted basal tumour cells toward a less aggressive state and improved their response to gemcitabine chemotherapy in preclinical models.
Important context: These findings are preclinical — validated in lab models and patient-derived organoids, not yet in human clinical trials. They represent promising early-stage science rather than an available treatment option.
How genomic profiling is transforming cancer treatment — and why understanding your tumour's molecular fingerprint matters.
Cancer treatment has historically been guided primarily by the location and histology of the tumour. Patients diagnosed with the same type of cancer often received similar treatment strategies, typically involving combinations of surgery, chemotherapy, and radiation therapy. Over the past decade, however, a new approach has emerged: precision oncology.
Precision oncology focuses on understanding the molecular characteristics of an individual tumour. Instead of treating cancers solely based on where they arise in the body, clinicians can now examine the genetic alterations and molecular pathways driving tumour growth.
Advances in next-generation sequencing (NGS) have made it possible to analyse hundreds of cancer-related genes simultaneously. Comprehensive genomic profiling can identify mutations, gene amplifications, gene fusions, and other alterations that may help guide treatment decisions.
Tumours harbouring specific alterations in genes involved in signalling pathways, DNA repair, or immune regulation may respond to targeted therapies or immunotherapy designed to exploit these vulnerabilities. Molecular profiling can also help determine whether a patient may be eligible for clinical trials investigating novel targeted treatments.
Genomic reports often contain numerous genetic alterations. Distinguishing clinically actionable findings from passenger mutations requires careful interpretation of scientific evidence, clinical guidelines, and the patient's clinical context.
Integrating molecular data with pathology findings, imaging results, and clinical history has become increasingly important — and is at the core of what precision oncology consultants do.
Precision oncology represents a shift toward more individualised cancer care, where treatment decisions are informed not only by tumour type but also by the unique molecular features of each patient's disease. While genomic profiling does not replace traditional cancer therapies, it provides an additional layer of insight that can help clinicians and patients explore more personalised treatment strategies and potential therapeutic opportunities.
Two of oncology's most powerful tools — Antibody-Drug Conjugates (ADCs) and immune checkpoint inhibitors (ICIs) — are now being studied together. The science behind this combination is compelling: each therapy enhances the other in a self-reinforcing cycle that attacks cancer from multiple angles simultaneously.
ADCs kill cancer cells in a way that teaches the immune system to recognize and attack them — a process called immunogenic cell death. Adding an ICI then removes the "brakes" that cancer uses to suppress that immune response.
This combination is particularly relevant in cancers like HER2-positive and triple-negative breast cancer, where clinical trials are showing early promise for patients who have not responded to standard therapies.
A landmark 2025 study in Cancer Discovery found that consuming sucralose — a common artificial sweetener found in diet sodas, protein powders, and sugar-free foods — was significantly associated with poorer immunotherapy response in patients with melanoma and lung cancer.
Researchers at the University of Pittsburgh studied 132 patients receiving anti-PD-1 checkpoint inhibitor therapy and found a striking pattern: patients with higher sucralose intake responded significantly worse to treatment — and had shorter survival — than those who consumed little or none.
In melanoma patients, median progression-free survival was 13 months in low sucralose consumers vs. only 8 months in high consumers. In lung cancer (NSCLC), the gap was even wider: 18 months vs. 7 months.
The mechanism isn't that sucralose directly attacks immune cells — it's more subtle and more systemic. Sucralose disrupts the gut microbiome, causing an overgrowth of bacteria that break down arginine, an amino acid that T-cells critically depend on to function. Without enough arginine, T-cells become exhausted — unable to find and destroy cancer cells even when immunotherapy removes the brakes.
A landmark 2026 study in Nature Cancer used advanced imaging technology to map the tumour's immune landscape — and found that what happens during treatment predicts response far better than anything measurable before it begins.
Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes, and immune checkpoint inhibitors (ICI) — drugs that release the immune system's brakes — have transformed its treatment. Yet only a fraction of patients truly respond. The critical question has always been: who will benefit?
Scientists from Stanford and The Netherlands Cancer Institute analyzed tumour biopsies from 103 patients with metastatic TNBC across four time points — including the primary tumour, before treatment, and during immunotherapy. Using highly multiplexed imaging (MIBI), they simultaneously measured 37 proteins in each tumour sample to map the full immune landscape.
They built an open-source tool called SpaceCat to extract over 800 features from these images — not just which immune cells are present, but where they are, how they're organized, and how they interact with cancer cells. The result was the most detailed spatial picture of the metastatic TNBC tumour microenvironment to date.
The primary tumour — the cancer at diagnosis — was almost useless for predicting who would respond to immunotherapy later, in the metastatic setting. On-treatment biopsies, taken after three cycles of nivolumab, were dramatically more informative, achieving a prediction accuracy (AUC) of 0.90.
This challenges the common assumption that pre-treatment biopsies are sufficient. The tumour microenvironment evolves — and the immune response that unfolds during early treatment is the most reliable window into whether therapy will work.
Immunotherapy has transformed cancer treatment — but it has also introduced new complexities in how response is assessed. An apparent increase in tumour size shortly after therapy begins may not represent treatment failure. Understanding the difference could mean the difference between staying on life-prolonging therapy or stopping it prematurely.
Unlike conventional chemotherapy, immune checkpoint inhibitors activate the body's own immune system to fight cancer. This fundamentally different mechanism produces imaging patterns that can be alarming — and deeply misleading — if not properly understood.
Pseudoprogression refers to a transient increase in tumour size or the appearance of new lesions on imaging, followed by subsequent tumour regression — without any change in therapy. It is most commonly seen with PD-1, PD-L1, and CTLA-4 inhibitors and reflects immune-mediated effects rather than true disease worsening: infiltration of activated T cells, inflammation, oedema, and tumour necrosis all alter how lesions appear on a scan.
The mechanism is rooted in immune activation within the tumour microenvironment. After immunotherapy begins, activated immune cells infiltrate the tumour. The resulting inflammatory response increases lesion volume. Necrotic changes further alter how the tumour appears on imaging.
As a result, radiographic findings may temporarily suggest tumour growth — even when the overall tumour burden is biologically decreasing.
Pseudoprogression typically occurs within the first 6–12 weeks of therapy. Genuine tumour shrinkage, however, may only become evident months later — making early imaging particularly prone to misinterpretation. Delayed responses are not uncommon.
Standard response criteria — RECIST — were developed for cytotoxic chemotherapy. Under these criteria, an increase in tumour size is classified as progressive disease, which typically triggers a switch to a different regimen.
Applied to immunotherapy, this creates a serious risk of misclassification. A patient on the path to a genuine, durable response may be told their treatment is failing — and switched to something less effective.
Recognising the limitations of RECIST, immune-specific response criteria (iRECIST) have been developed. Under iRECIST, initial radiographic worsening is classified as "unconfirmed progression" — treatment may continue if the patient is clinically stable, with a confirmatory scan 4–8 weeks later. This framework allows clinicians to treat beyond initial apparent progression when appropriate, preventing early cessation of potentially life-prolonging therapy.
No single parameter is definitive. Accurate interpretation requires a multidimensional clinical approach, integrating converging evidence from multiple sources.